Pfizer
pfizer.comTotal trials
3,073
Capped at 5,000
Active
198
Phase 3
660
Total enrollment
52,594,130
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 246 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| crizotinib | — | — | 24 | ||||
| Lorlatinib | — | — | 15 | ||||
| Binimetinib only treatment | — | — | — | — | — | 1 | |
| Encorafenib only Treatment | — | — | — | — | — | 1 | |
| Encorafenib & Binimetinib Treatment | — | — | — | — | — | 1 | |
| Treatment of Encorafenib & Binimetinib & Ribociclib | — | — | — | — | — | 1 | |
| Treatment of Encorafenib & Binimetinib & Cetuximab | — | — | — | — | — | 1 | |
| TIVDAK | — | — | — | — | — | 1 | |
| PF-08634404 | — | — | — | — | 10 | ||
| Elranatamab | — | — | 15 | ||||
| Palbociclib | — | — | 20 | ||||
| PF-08653944 | — | — | — | 5 | |||
| Enzalutamide | — | 21 | |||||
| 20-valent pneumococcal conjugate vaccine | — | — | 13 | ||||
| Letrozole | — | — | 13 | ||||
| Ritlecitinib | — | — | 12 | ||||
| Etrasimod | — | — | — | 12 | |||
| Pembrolizumab | — | — | 11 | ||||
| Chemotherapy | — | — | — | — | 8 | ||
| vepdegestrant | — | — | — | 7 | |||
| PF-07220060 | — | — | — | 7 | |||
| Abrocitinib | — | — | — | 8 | |||
| Ritlecitinib 100 mg | — | — | — | — | 3 | ||
| Dexamethasone | — | — | — | — | — | 3 | |
| Rimegepant | — | — | 17 | ||||
| Bevacizumab | — | — | 12 | ||||
| marstacimab | — | — | — | 3 | |||
| Abemaciclib | — | — | — | 3 | |||
| RSVpreF | — | — | — | 7 | |||
| VLA15 | — | — | — | — | 6 | ||
| pemetrexed | — | — | — | 5 | |||
| PF-06801591 | — | — | — | 4 | |||
| Osivelotor | — | — | — | — | 4 | ||
| MET097 | — | — | — | — | 4 | ||
| Lenalidomide | — | — | — | — | 3 | ||
| Ritlecitinib 50 mg | — | — | — | 3 | |||
| PG4 | — | — | — | — | 3 | ||
| ibuzatrelvir | — | — | — | — | 3 | ||
| Daratumumab | — | — | — | — | — | 2 | |
| Bortezomib | — | — | — | — | — | 2 |
206 more active programs hidden
Next readouts
- 2022-03-03
- 2022-06-17
- 2022-10-03
- 2022-11-16
- 2023-01-31
- 2023-05-04
- 2023-07-17
- 2024-05-15
- 2024-08-26
- 2024-12-02
Top conditions
- Healthy331
- Healthy Volunteers94
- Rheumatoid Arthritis63
- Breast Neoplasms52
- Healthy Participants48
- Pain45
- Breast Cancer40
- Diabetes Mellitus, Type 234
Frequently asked questions about Pfizer
- How many clinical trials does Pfizer have on ClinicalTrials.gov?
- Pfizer is listed as the lead sponsor on 3,073 clinical trials in ClinicalTrials.gov, 198 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Pfizer's trials are in Phase 3?
- 660 of Pfizer's trials are in Phase 3, spread across 246 active drug programs.
- What therapeutic areas does Pfizer focus on?
- Pfizer's most-studied conditions on ClinicalTrials.gov are Healthy, Healthy Volunteers, Rheumatoid Arthritis, Breast Neoplasms, Healthy Participants.
- When are Pfizer's next clinical trial readouts?
- Pfizer has 10 upcoming primary-completion readouts tracked here; the soonest is “Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies”, expected around 2022-03-03.